Product image of Ondameton (Ondansetron) supplied by GNH India

Ondameton

Active Ingredient:
Ondansetron
Origin:
EU

Ondameton (Ondansetron)

Ondansetron, the active ingredient in Ondameton, is a 5-HT3 receptor antagonist presented as a 4 mg tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy and surgery in adult and paediatric patients.
GNH India supplies Ondameton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Medicina Pharmaceuticals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ondameton is a selective 5‑HT3 receptor antagonist used in the management of several nausea‑vomiting pathways.

  • Chemotherapy‑induced nausea and vomiting (CINV): helps prevent and control acute and delayed episodes.
  • Radiotherapy‑induced nausea and vomiting (RINV): reduces the frequency and severity of symptoms.
  • Post‑operative nausea and vomiting (PONV): decreases incidence of nausea after surgical procedures.

How It Works

  • Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By competitively inhibiting these receptors, it prevents serotonin‑mediated stimulation of the vomiting centre, thereby reducing nausea and vomiting.

Side Effects

Adverse reactions to ondansetron are generally mild to moderate and vary with the route and dose.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Constipation: occasional bowel habit changes.
  • Diarrhoea: loose stools reported in some patients.
  • Fatigue: feeling of tiredness or reduced energy.
  • Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects

  • Cardiac arrhythmia: QT‑interval prolongation, especially with IV administration.
  • Severe hypersensitivity: rash, itching, swelling or anaphylaxis.
  • Serotonin syndrome: rare when combined with other serotonergic agents.
  • Hepatic enzyme elevation: abnormal liver function tests.
  • Neuroleptic malignant‑like reactions: extremely rare but potentially life‑threatening.

Precautions & Warnings

When prescribing Ondameton, clinicians should consider several safety aspects.

  • Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk.
  • Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use.
  • Concomitant serotonergic drugs: evaluate for serotonin syndrome risk.
  • Pregnancy: use only if clearly needed; weigh maternal benefit against potential fetal risk.
  • Breastfeeding: monitor infant for possible sedation or gastrointestinal effects.
  • Store at below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Ondameton may interact with other medicines that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid)

  • Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.
  • Certain antipsychotics (e.g., haloperidol, droperdroge).
  • Macrolide antibiotics (e.g., erythromycin, clarithromycin): may elevate plasma levels.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole, fluconazole).
  • CYP2D6 substrates (such as codeine) that may have altered metabolism.
  • Serotonergic agents (e.g., tramadol, duloxetine).
  • Diuretics that affect electrolyte status.
  • Other anti‑emetics (e.g., dexamethasone) used in combination protocols.

Frequently Asked Questions

Ondameton contains ondansetron, a medication used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy and surgery. It is commonly prescribed in oncology, radiology and peri‑operative settings to improve patient comfort and reduce the risk of dehydration or treatment interruption.

Ondansetron works by selectively blocking serotonin type‑3 (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. This inhibition stops serotonin‑driven signals from activating the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The dose of Ondameton is determined by the prescribing clinician based on the indication, patient age, weight and renal function. Healthcare professionals follow established guidelines and adjust the regimen to achieve optimal anti‑emetic control while monitoring safety.

Ondameton should be used in pregnancy only when the potential benefit justifies any potential risk to the fetus. Limited data exist, so clinicians weigh maternal needs against unknown fetal effects. While breastfeeding, small amounts may pass into milk; infants should be observed for sedation or gastrointestinal changes.

To order Ondameton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Ondameton (ondansetron) is a selective 5‑HT3 antagonist, offering rapid onset and effective control of both acute and delayed nausea. Compared with dopamine antagonists such as metoclopramide, ondansetron has a lower risk of extrapyramidal side effects and is preferred for chemotherapy‑induced nausea.

Ondameton tablets should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and light. Maintaining these conditions preserves potency and ensures the product remains stable throughout its shelf life.

Ondameton is supplied as oral tablets that are swallowed whole with water. Depending on the clinical protocol, tablets may be taken shortly before chemotherapy, radiotherapy or surgery, and may be repeated as directed by the treating physician.

The most serious risks include QT‑interval prolongation leading to cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis, and rare cases of serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for cardiac symptoms and allergic signs.

Ondameton is contraindicated in patients with known hypersensitivity to ondansetron or any component of the formulation. Caution is also advised for individuals with congenital long QT syndrome, uncontrolled electrolyte disturbances, or those taking medications that significantly prolong the QT interval.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT